Three months of rifapentine and isoniazid for latent tuberculosis infection.

By T. Sterling, M. E. Villarino, A. Borisov, N. Shang, F. Gordin, Erin Bliven-Sizemore, J. Hackman, C. Hamilton, D. Menzies, Amy Kerrigan and 7 more. New England Journal of Medicine, 2011

875 citations recorded by the source corpus.

Subfields: Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/c4bed29cb6eb31e624eef7c30b6b5d0630b5b7f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Glaziou
2. K. Lönnroth
3. I. Abubakar
4. M. Uplekar
5. Alimuddin Zumla
6. L. D’Ambrosio
7. D. Weil
8. G. de Vries

Citations in the corpus

• Towards tuberculosis elimination: an action framework for low-incidence countries (2015, background): “Recently, a regimen of 3 months’ intermittent treatment with rifapentine and isoniazid showed similar efficacy, a lower rate of permanent drug discontinuation owing to an adverse event and lower rates of investigator-assessed drug-related hepatotoxicity (68).”
• Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts (2021, background): “The development of new regimens that are shorter and equally effective such as a weekly dose of rifapentine and isoniazid for 3 months (3HP), a daily dose of rifampicin plus isoniazid for 3 months (3HR), a daily dose of rifapentine plus isoniazid for 1 month (1HP), a daily dose of rifampicin for 4 m”
• Tuberculosis in children (2014, background): “cious in adults (Sterling et al. 2011), but is not yet recommended in children of ,12 yr of age awaiting safety data.”